Nathan D. Trinklein
Fondateur chez SwitchGear Genomics, Inc.
Profil
Nathan D.
Trinklein is the founder.
He founded SwitchGear Genomics, Inc. in 2006 and currently holds the title of Chief Executive Officer & Director.
He also founded Rondo Therapeutics, Inc. in 2021 and currently holds the title of President & Chief Scientific Officer.
Dr. Trinklein obtained a doctorate degree from Stanford University.
Postes actifs de Nathan D. Trinklein
| Sociétés | Poste | Début |
|---|---|---|
SwitchGear Genomics, Inc.
 SwitchGear Genomics, Inc. BiotechnologyHealth Technology SwitchGear Genomics, Inc. provides products for studying regulatory elements in the human genome. It launches LightSwitch Synthetic Response Element which is used for understanding transcription factor activity in living cells. The firms endogenous human promoter vectors are used in primary screening assays to understand how drug candidates may affect biological pathways. The company was founded by Richard M. Myers, Nathan D. Trinklein and Shelley Force Aldred in 2006 and is headquartered in Menlo Park, CA. | Fondateur | 01/01/2006 |
Rondo Therapeutics, Inc.
 Rondo Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Rondo Therapeutics, Inc. develops bispecific therapeutic antibodies to fight cancer. The American company was founded by Nathan D. Trinklein, Shelley Force Aldred. Shelley Force Aldred has been the CEO since incorporation. | Fondateur | 01/08/2021 |
Formation de Nathan D. Trinklein
| Stanford University | Doctorate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
SwitchGear Genomics, Inc.
SwitchGear Genomics, Inc. BiotechnologyHealth Technology SwitchGear Genomics, Inc. provides products for studying regulatory elements in the human genome. It launches LightSwitch Synthetic Response Element which is used for understanding transcription factor activity in living cells. The firms endogenous human promoter vectors are used in primary screening assays to understand how drug candidates may affect biological pathways. The company was founded by Richard M. Myers, Nathan D. Trinklein and Shelley Force Aldred in 2006 and is headquartered in Menlo Park, CA. | Health Technology |
Rondo Therapeutics, Inc.
Rondo Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Rondo Therapeutics, Inc. develops bispecific therapeutic antibodies to fight cancer. The American company was founded by Nathan D. Trinklein, Shelley Force Aldred. Shelley Force Aldred has been the CEO since incorporation. | Commercial Services |
